KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 99 filers reported holding KEROS THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $741,752 | -26.3% | 23,267 | -7.2% | 0.00% | 0.0% |
| Q2 2023 | $1,006,911 | +8.8% | 25,060 | +15.6% | 0.00% | 0.0% |
| Q1 2023 | $925,394 | -8.7% | 21,672 | +2.7% | 0.00% | -50.0% |
| Q4 2022 | $1,013,510 | +38.1% | 21,106 | +8.2% | 0.00% | +100.0% |
| Q3 2022 | $734,000 | +38.8% | 19,511 | +1.9% | 0.00% | 0.0% |
| Q2 2022 | $529,000 | -45.0% | 19,147 | +8.4% | 0.00% | 0.0% |
| Q1 2022 | $961,000 | -15.0% | 17,670 | -8.5% | 0.00% | 0.0% |
| Q4 2021 | $1,130,000 | +51.3% | 19,317 | +2.2% | 0.00% | 0.0% |
| Q3 2021 | $747,000 | -18.3% | 18,895 | -12.2% | 0.00% | 0.0% |
| Q2 2021 | $914,000 | -25.5% | 21,519 | +8.0% | 0.00% | -50.0% |
| Q1 2021 | $1,227,000 | -11.8% | 19,931 | +1.0% | 0.00% | 0.0% |
| Q4 2020 | $1,391,000 | +243.5% | 19,724 | +87.8% | 0.00% | +100.0% |
| Q3 2020 | $405,000 | +2.8% | 10,503 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $394,000 | – | 10,503 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CHI Advisors LLC | 407,633 | $12,995,340 | 5.15% |
| Opaleye Management Inc. | 360,400 | $11,489,552 | 3.74% |
| Parkman Healthcare Partners LLC | 298,475 | $9,515,383 | 1.74% |
| BRAIDWELL LP | 1,357,309 | $43,271,011 | 1.37% |
| First Light Asset Management, LLC | 421,438 | $13,435,443 | 1.28% |
| Orbimed Advisors | 1,514,734 | $48,289,720 | 1.03% |
| Yiheng Capital Management, L.P. | 554,151 | $17,666,334 | 0.90% |
| Nantahala Capital Management | 328,781 | $10,481,538 | 0.90% |
| DAFNA Capital Management LLC | 65,961 | $2,102,837 | 0.65% |
| EDBI Pte Ltd | 10,105 | $322,147 | 0.35% |